HC Wainwright has downgraded Aclaris Therapeutics Inc ACRS. Earlier this month, the company released topline results from its Phase 2b study of ATI-1777, an investigational topical “soft” JAK 1/3 inhibitor, in patients…
The Federal Reserve is driving the market bus. Rate cut expectations have been re-drawn, and the “buy everything” sentiment that powered equity indices higher in the final quarter of 2023…
The U.S. Food and Drug Administration has recently issued a stern warning to the public, advising against the purchase and use of multiple specific over-the-counter eye drop products from prominent brands. The agency…